Patent: 5,849,700
✉ Email this page to a colleague
Summary for Patent: 5,849,700
| Title: | Pharmaceutical formulation |
| Abstract: | A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods. |
| Inventor(s): | Hans Holmegaard S.o slashed.rensen, Lars Skriver, Annie Rassing Hoelgaard |
| Assignee: | Novo Nordisk Health Care AG |
| Application Number: | US08/458,385 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,849,700
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | NORDITROPIN | somatropin | Injection | 021148 | June 20, 2000 | 5,849,700 | 2015-06-02 |
| Novo Nordisk Inc. | NORDITROPIN | somatropin | Injection | 021148 | October 01, 2004 | 5,849,700 | 2015-06-02 |
| Novo Nordisk Inc. | NORDITROPIN | somatropin | Injection | 021148 | March 10, 2009 | 5,849,700 | 2015-06-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,849,700
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | E227583 | ⤷ Start Trial |
| Austria | E368472 | ⤷ Start Trial |
| Australia | 3344693 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
